Lv1
10 积分 2022-02-24 加入
Immune checkpoint inhibitors in high-grade gastroenteropancreatic neuroendocrine neoplasms
7小时前
待确认
In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy
1个月前
已完结
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort
1年前
已完结
Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms
1年前
已完结
Tyrosine kinase inhibitors and immunotherapy updates in neuroendocrine neoplasms
1年前
已完结
Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors
1年前
已完结
Enhancing in situ cancer vaccines using delivery technologies
1年前
已完结
Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data
1年前
已完结
Clinical implications of T cell exhaustion for cancer immunotherapy
1年前
已完结
In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity
1年前
已完结
皖公网安备34019202002308
